QBiotics appoints Sergio Duchini as Non-executive Director
BRISBANE, 30 June, 2025
QBiotics Group Limited (QBiotics) is pleased to announce the appointment of Mr Sergio Duchini to its Board as a Non-executive Director, effective 1 July 2025.
Sergio brings more than 30 years of executive and board-level experience spanning biotechnology, healthcare, technology, and professional services. He currently serves as Non-executive Chair of Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotech company advancing NUZ-001 for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. He is also a Non-executive Director and Chair of the Audit and Risk Committee for Enlitic Inc (ASX: ENL), an AI-driven medical imaging business.
Sergio’s previous governance roles include serving as Chair of Lymphoma Australia (2019–2024), Non-executive Director and Risk & Audit Committee Chair of AusBiotech, and a former Board Member of Deloitte Australia, where he chaired the Remuneration Committee and was a member of the National Diversity and Inclusion Council. He also has over 30 years of professional services experience, including 23 years as a Deloitte Tax Partner. During his tenure at Deloitte, he advised on innovation strategy, R&D investments, M&A and played an important role in the integration of Deloitte Asia Pacific.
A Chartered Accountant, Chartered Tax Adviser, and Graduate of the Australian Institute of Company Directors, Sergio is recognised for his strategic leadership, commitment to governance excellence, and expertise in innovation, commercialisation, and translational research.
QBiotics’ Chair, Mark Fladrich said of the appointment, “On behalf of my fellow directors, we are delighted to welcome Sergio to the Board of QBiotics. His deep experience across biotechnology, healthcare and professional services, combined with his proven governance and strategic insights will be invaluable in supporting our clinical and commercial progress.”
Sergio Duchini commented, “I’m delighted to be joining the Board of QBiotics at this important stage in its history. I have long admired QBiotics’ pioneering science and have been impressed by the strength of its innovation platform, translational capability, and commitment to delivering real-world impact. I look forward to contributing to QBiotics’ continued growth and global aspirations.”
—ends—
FURTHER INFORMATION STEPHEN DOYLE, CEO & MANAGING DIRECTOR
or
MEDIA ENQUIRIES JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774
NOTES FOR EDITORS
ABOUT QBIOTICS
QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialisation to harness the power of nature to treat diseases of high unmet need.
Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program.
QBiotics’ lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumours. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024.
A veterinary formulation of tigilanol tiglate (STELFONTA®) is approved for the treatment of canine mast cell tumours (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA®.
Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment.
For more, head to: QBiotics.com or LinkedIn